Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Daratumumab with IRd in NDMM displays excellent activity

Morie Gertz • 7 Dec 2019
ASH 2019
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Ixazomib Lenalidomide

Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, discusses a phase II trial (NCT03012880) designed to examine the safety and efficacy of daratumumab in combination with an all-oral regimen of ixazomib, lenalidomide and modified dose dexamethasone (IRd) in newly diagnosed multiple myeloma (NDMM). Dr Gertz outlines the advantages of this drug regimen and reveals that the combination of daratumumab with IRd is well-tolerated and exhibits excellent activity, including in patients with high-risk genetics. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Morie Gertz

1:36
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz • 21 Nov 2022
1:33
The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz • 21 Nov 2022
1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz • 21 Nov 2022
1:37
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
Morie Gertz • 21 Nov 2022

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals